Lupus Innovation Award (LIA)
The Lupus Innovation Award ($300,000 for 2 years) provides early-stage support for highly innovative approaches to major challenges in lupus research. If you are a researcher and would like to learn more about our funded research please click here.
Lupus Therapeutics Announces Collaboration to Support the Evaluation of Non-Genetically Modified Cell-Based Therapy for Lupus Nephritis with Artiva Biotherapeutics
NEW YORK, N.Y. — [March 14, 2024]: Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announced a collaboration with Artiva Biotherapeutics, Inc. on a Phase 1 trial of the company novel NK cell-based therapy AlloNK® (also known as AB-101), in combination with anti-CD20 antibodies, for patients with active lupus nephritis – inflammation […]
Lupus Mechanisms and Targets Award (LMTA)
The Lupus Mechanisms and Targets Award ($600,000 for 3 years) supports research focused on the identification and/or investigation of molecular pathways or targets that could lead to new or improved therapies for people with lupus. If you are a researcher and would like to learn more about our funded research please click here.
Good News on Lupus Nephritis Discoveries from ACR Convergence 2020
November 19, 2020 The LRA is proud to share the extraordinary work presented at ACR Convergence 2020 by research members of the Accelerating Medicines Partnership Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) program (AMP RA/SLE). AMP is a public-private partnership between the National Institutes of Health (NIH), eight biopharmaceutical companies, the LRA and several […]
Lupus Research Alliance Announces Recipients of the Lupus Mechanisms and Targets Award
New York, NY, February 28. The Lupus Research Alliance (LRA) is pleased to announce the recent recipients of the Lupus Mechanisms and Targets Award (LMTA), whose research will investigate molecular pathways or targets that will lead to new or improved therapies for individuals with systemic lupus erythematosus (SLE). The LMTA provides investigators up to $600,000 […]
Lupus Nephritis: A Major Focus at the Lupus Research Alliance
Updated March, 2022 Developing safe and effective treatments for lupus nephritis has been an urgent and long-standing goal in the lupus community. As the leading private funding agency for lupus research, the LRA and its legacy organizations have dedicated significant focus and resources towards addressing this continued challenge, awarding over 40 grants to address this […]
Re-engineering Immune Cells Opens Door to Promising Therapy for Lupus Kidney Inflammation
Research Published in Nature Communications and Funded in Part by the Lupus Research Alliance Could Correct a Defect in Lupus NEW YORK, NY. February 6. Research featured in Nature Communications highlights a novel approach that re-engineers a person’s own immune cells to suppress the overactive immune system that occurs in lupus nephritis, a serious and potentially […]
LRA Highlights Full Continuum of Lupus Research at ACR Convergence 2020
30+ presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways Results from three clinical studies conducted in part by LRA-affiliate Lupus Therapeutics (LT) through its trials network 10 lupus presentations by the Accelerating Medicines Partnership Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) program (AMP RA/SLE) NEW YORK, NY, […]
LRA Highlights Groundbreaking Lupus Research at ACR Convergence 2023
This information is brought to you by the Lupus Research Alliance and Lupus Therapeutics and is not sponsored by, nor a part of, the American College of Rheumatology. 30+ presentations of studies funded by the LRA spanning a broad spectrum of research areas Positive results from Phase 2/3 clinical studies supported by LRA affiliate Lupus Therapeutics point to […]
Pharmaceutical and Biotech Support of the Lupus Research Alliance – 2019
Pharmaceutical and Biotech Support of the Lupus Research Alliance – 2019 The Lupus Research Alliance’s vision is a world free of lupus – by finding ways to prevent, treat and one day cure this disease. We work diligently to forge appropriate relationships with members of the pharmaceutical and biotech industries that share our vision and […]